 |
|
|
| |
Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate
|
| |
| |
Reported by jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Young-Suk Lim, 1 Tatsuya Ide, 2 Simone I. Strasser, 3 Ki-Tae Yoon, 4 Seung Woon Paik, 5 John F. Flaherty, 6 Kyungpil Kim, 6 Anuj Gaggar, 6 G. Mani Subramanian, 6 Alessandra Mangia, 7 Krzysztof Simon, 8 Peter Kwan, 9 Edward J. Gane 10
1Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 2Kurume University Hospital, Kurume, Japan; 3AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, New Zealand; 4Pusan National University Hospital, Busan-si, Korea; 5Samsung Medical Center, Seoul, Korea;
6Gilead Sciences, Inc., Foster City, CA; 7Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; 8Klinika Chorób Zakaznych Akademia Medyczna, Wroclaw, Poland; 9Gordon and Leslie Diamond Health Care Centre, University of British Columbia, Vancouver, Canada; 10Auckland City Hospital, Auckland, New Zealand
References
1. Lampertico P, et al. Aliment Pharmacol Ther 2016;44:16-34; 2. Marcellin P, et al. EASL 2014, oral; 3. Bam RA, et al. Antivir Ther 2014;19:687-92; 4. Hall AM, et al. Am J Kidney Dis 2011;773-80; 5. Buti M, et al. Lancet Gastroenterol Hepatol In press; 6. Chan HLY, et al. Lancet Gastroenterol Hepatol In press; 7. Mills A, et al. Lancet Infect Dis 2016;16:43-52; 8. Sax P, et al. Lancet 2015;385:2606-15; 9. Babusis D, et al. Mol Pharm 2013;10:459-66; 10. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 11. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 12. Agarwal K, et al. J Hepatol 2015;62:533-40; 13. Terrault NA, et al. Hepatology 2016;63:261-83; 14. Go AS, et al. N Engl J Med 2004;351:1296-305.
|
| |
|
|
|
|
|
